Event > Webinar >
Addressing Unmet DILI Challenges: Novel insights from adaptable Liver microphysiological systems
Discover how Liver MPS address unmet DILI challenges – from cross‑species comparisons to evaluating cholestatic and complex mechanistic risks. Explore how MPS strengthen toxicology workflows, reduce translational risk, and improve confidence in human safety outcomes.
Drug-induced liver injury (DILI) remains a major challenge in drug development, especially when traditional models fail to capture complex or species-specific risks. Addressing these unmet workflow limitations is essential for improving confidence in drug safety assessment, particularly for multifaceted liabilities such as DILI.
In this webinar, we will demonstrates how Liver microphysiological systems (MPS) can be adapted to investigate different areas of toxicology – from lead optimization screening to identifying and understanding species-specific risks, informing study design and supporting mechanistic investigations of adverse DILI events in humans.
Drawing on recent peer‑reviewed studies, we will present a case example showing how Liver MPS studies compare across human and preclinical animal species. We will also explore challenges in evaluating cholestatic drug effects that cause DILI. Using a side-by-side comparison of multiple Liver MPS configurations, we will highlight how biological fidelity varies across systems and what is required for robust and reliable mechanistic cholestasis research.
Attendees will gain insight into where MPS adds the most value for reducing translational risk and increasing confidence in human safety outcomes.
Key Learning on how Liver MPS are used to address unmet DILI challenges:
- Understand the importance of using MPS for cross-species DILI comparisons
- Learn how MPS enables more complex and latent DILI effects to be unlocked
- Explore what’s required of an MPS to evaluate cholestatic drug effects
- See how to adopt and adapt MPS for different areas of toxicology and safety testing
About the Presenter:
Dr. Emily Richardson
Dr. Emily Richardson is driving development of MPS for toxicology and safety assessment. She led the development of CN Bio’s Lung and Lung/Liver models for infectious disease research and inhaled therapeutics, and spearheaded multiple other collaborative and grant-funded programmes, published peer-reviewed papers, and contributed to advancing regulatory acceptance of Organ-on-a-chip.
Her work bridges complex cell biology and real-world drug discovery, informed by a PhD from the University of Leicester in 3D cell culture for metastatic lung cancer and a BSc in Biochemistry and Molecular Medicine degree from the University of Nottingham.